Bioengineered Hydrogels for Regenerative Medicine

Abstract

Hydrogels, highly hydrated cross-linked polymer networks, have emerged as powerful synthetic analogs of extracellular matrices for basic cell studies as well as promising biomaterials for regenerative medicine applications. A critical advantage of these synthetic matrices over natural networks is that bioactive functionalities, such as cell adhesive sequences and growth factors, can be incorporated in precise densities while the substrate mechanical properties are independently controlled. We have engineered poly(ethylene glycol) [PEG]-maleimide hydrogels for local delivery of therapeutic proteins and cells in several regenerative medicine applications. For example, synthetic hydrogels with optimal biochemical and biophysical properties have been engineered to direct human stem cell-derived intestinal organoid growth and differentiation, and these biomaterials serve as injectable delivery vehicles that promote organoid engraftment and repair of intestinal wounds. In another application, hydrogels presenting immunomodulatory proteins induce immune acceptance of allogeneic pancreatic islets and reverse hyperglycemia in models of type 1 diabetes. Finally, photopatterned hydrogel-based microfluidic platforms have been developed using human organoids to model lymphoid-gut interactions. These studies establish these biofunctional hydrogels as promising platforms for basic science studies and biomaterial carriers for cell delivery, engraftment and enhanced tissue repair.

Bio

Andrés J. García is the Executive Director of the Petit Institute for Bioengineering and Bioscience and Regents’ Professor at the Georgia Institute of Technology. Dr. García’s research program integrates innovative engineering, materials science, and cell biology concepts and technologies to create cell-instructive biomaterials for regenerative medicine and generate new knowledge in mechanobiology. This cross-disciplinary effort has resulted in innovative biomaterial platforms that elicit targeted cellular responses and tissue repair, human stem cell technologies, and mechanistic insights into the interplay of mechanics and cell biology. In addition, his research has generated intellectual property and licensing agreements with start-up and multi-national companies. He is a co-founder of 5 start-up companies. He has received several distinctions, including the Young Investigator Award, the Clemson Award for Basic Science, and the Founders Award from the Society for Biomaterials; the International Award from the European Society for Biomaterials; the Biomaterials Global Impact Award; and Georgia Tech’s Outstanding Interdisciplinary Activities Award and the Class of 1934 Distinguished Professor Award. He is an elected Fellow of Biomaterials Science and Engineering, Fellow of the American Association for the Advancement of Science, Fellow of the American Society of Mechanical Engineers, and Fellow of the American Institute for Medical and Biological Engineering. He served as President for the Society for Biomaterials in 2018-2019. He is an elected member of the National Academy of Engineering, the National Academy of Medicine, and the National Academy of Inventors.

Related Info

Register Now

Please join us for the annual BME Jaharis Lecture.

Dr. Omid Veiseh from Rice University presents "Bioengineering Cell-based Therapeutics"

Abstract: Cell-based therapeutics are an emerging modality that can potentially treat many currently intractable diseases through uniquely powerful modes of action. Our group is innovating new biomaterials and cellular constructs for medicine and biology by combining chemical biology, cellular engineering, and multi-scale fabrication. We have pioneered innovative approaches to synthesizing and in vivo screening of large libraries of biomaterial formulations for tailored applications in immunology and medicine. In my talk, I will describe our advances in discovering immunomodulatory biomaterials that can interact appropriately with the host immune system for localized immunomodulation. I will highlight our efforts to develop “cytokine factories” locally activating the innate and adaptive immune response to generate systemic immunotherapy and eradicate metastatic cancer. This approach has advanced to phase I/II human clinical trials for treating recurrent, refractory ovarian cancer.

Bio: Dr. Omid Veiseh, Ph.D., is a Professor and CPRIT Scholar in Cancer Research in the Departments of Bioengineering and Chemical and Biomolecular Engineering at Rice University. He is also the Director of Rice University's Biotech Launch Pad, a new initiative with a mission to accelerate the translation of Rice University discoveries and technologies into clinical practice to provide rapid patient access to leading-edge therapeutic products. He leads an interdisciplinary translational research program to engineer and commercialize next-generation cell-based therapeutics for various human diseases. His team leverages the latest techniques in synthetic biology, immunoengineering, and materials science to develop innovative cell-based platforms for real-time and feedback-regulated production of biologics. Throughout his career, he has authored or co-authored more than 80 peer-reviewed publications, including those in Nature, Nature Biotechnology, Nature Materials, Nature Medicine, and Nature Biomedical Engineering. He is an inventor on more than 50 pending or awarded patents. He is also a serial entrepreneur who has co-founded multiple biotechnology companies, collectively attracting ~ $500M in private and public investment capital. Dr. Veiseh has been elected as a fellow of the Controlled Release Society and a member of the National Academy of Inventors.

Register Now